Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  OrbiMed Israel GP Ltd.
 2. Date of Event Requiring Statement (Month/Day/Year)
05/09/2017		 3. Issuer Name and Ticker or Trading Symbol
Novus Therapeutics, Inc. [NVUS]
(Last)
(First)
(Middle)
89 MEDINAT HAYEHUDIM ST, BUILDING E, 11TH FLOOR		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

HERZLIYA, L3 4614001		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
OrbiMed Israel GP Ltd.
89 MEDINAT HAYEHUDIM ST
BUILDING E, 11TH FLOOR
HERZLIYA, L3 4614001		   X   X    
OrbiMed Israel BioFund GP Limited Partnership
89 MEDINAT HAYEHUDIM ST
BUILDING E, 11TH FLOOR
HERZLIYA, L3 4614001		   X   X    

Signatures

/s/ Ryan A. Murr, as attorney-in-fact for OrbiMed Israel GP Ltd. 05/11/2017
**Signature of Reporting Person Date
/s/ Ryan A. Murr, as attorney-in-fact for OrbiMed Israel BioFund Limited Partnership 05/11/2017
**Signature of Reporting Person Date

Explanation of Responses:

No securities are beneficially owned

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 
Remarks:
Exhibit List:
Exhibit 24.1 - Power of Attorney for OrbiMed Israel GP Ltd.
Exhibit 24.2 - Power of Attorney for OrbiMed BioFund Limited Partnership

This report on Form 3 is jointly filed by OrbiMed Israel GP Ltd. and OrbiMed Israel BioFund GP Limited Partnership. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report on Form 3 shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.